This website is for UK Healthcare Professionals only

This promotional website is for UK healthcare professionals involved in the care of patients with ovarian cancer.

This promotional website is for UK healthcare professionals involved in the care of patients with ovarian cancer.

You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for ELAHERE. Adverse event reporting information is at the bottom of this page.

 
1. ELAHERE SmPC

UK-ELAH-260244. Date of Preparation: August 2026

You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for ELAHERE. Adverse event reporting information is at the bottom of this page.

1. ELAHERE SmPC

UK-ELAH-260244. Date of Preparation: August 2026

UK-ELAH-260246. Date of Preparation: August 2026

How is ELAHERE (mirvetuximab soravtansine) designed to target and kill cancer cells?

1. ELAHERE attaches to the outside of the cell

2. After binding to FRα, ELAHERE is taken into the cell

3. ELAHERE releases a strong cancer-killing drug inside the cell

4. The cancer-killing drug can also impact other nearby cells that may or may not be cancerous

This animation illustrates the mechanism of action of ELAHERE in ovarian cancer, including folate receptor alpha (FRα) targeting, tumour cell binding and internalisation, lysosomal payload release, microtubule disruption, and the induction of apoptosis.

*Investigator’s choice chemotherapy (ICC)

†MIRASOL study design: A multicentre, open-label, randomised, Phase 3 study evaluating ELAHERE (N=227) vs standard single-agent ICC (paclitaxel, pegylated liposomal doxorubicin or topotecan; N=226). Eligible participants were 18 years of age or older with a confirmed diagnosis of platinum-resistant, high-grade serous ovarian cancer. Participants must have received one to three previous lines of systemic anticancer therapy and had disease progression while receiving or immediately after receiving the previous therapy. Platinum-resistant disease was defined as EOC that recurred within 6 months of the last dose of platinum. FRα-high was defined as ≥75% of viable tumour cells staining with ≥2+ membrane intensity. The primary endpoint was median PFS by investigator assessment (5.62 months for patients treated with ELAHERE vs 3.98 months for patients treated with ICC (HR=0.65 [95% CI: 0.52–0.81]; P<0.0001). Median OS was a key secondary endpoint (16.46 months for patients treated with ELAHERE vs 12.75 months for patients treated with ICC (HR=0.67 [95% CI: 0.50–0.89]; P=0.005).4,5


Abbreviations

ADC, antibody-drug conjugate; CI, confidence interval; EOC, epithelial ovarian cancer; FRα, folate receptor alpha; HR, hazard ratio; ICC, investigator’s choice chemotherapy; mDOR, median duration of response; OR, odds ratio; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; SmPC, summary of product characteristics.

References

  1. Cancer Research UK. Ovarian cancer statistics. Available at: https//www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-bycancer-type/ovarian-cancer [Accessed November 2026]
  2. Salani R.et al. AM J Obstet Gynecol. 2011:204(6):466-478
  3. St Laurent J & Liu JF. J Clin Onco. 2024:42(2):127-133
  4. ELAHERE SmPC
  5. Moore KN, et al. N Engl J Med. 2023: 389(23):2162-2174
  6. Eskander RN, et al. Front Oncol. 2023;13:1258228

By clicking the link above, you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

UK-ELAH-260247. Date of Preparation: November 2026

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to AbbVie on GBPV@abbvie.com

NICE Guidance (TA1169)1

Mirvetuximab soravtansine can be used, within its marketing authorisation, as an option to treat folate receptor-alpha (FRα) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults after one to three lines of systemic treatment. Mirvetuximab soravtansine can only be used if the company provides it according to the commercial arrangement.1

NICE Guidance (TA1169)1

Mirvetuximab soravtansine can be used, within its marketing authorisation, as an option to treat folate receptor-alpha (FRα) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults after one to three lines of systemic treatment. Mirvetuximab soravtansine can only be used if the company provides it according to the commercial arrangement.1

SMC accepted as a treatment option2

ELAHERE (MIRVETUXIMAB SORAVTANSINE) IS ACCEPTED FOR USE WITHIN NHS SCOTLAND.

Advice: following a full submission assessed under the end of life and orphan equivalent medicine process:

Indication under review: as monotherapy for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

This advice applies only in the context of an approved NHS Scotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.2

SMC accepted as a treatment option2

ELAHERE (MIRVETUXIMAB SORAVTANSINE) IS ACCEPTED FOR USE WITHIN NHS SCOTLAND.

Advice: following a full submission assessed under the end of life and orphan equivalent medicine process:

Indication under review: as monotherapy for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

This advice applies only in the context of an approved NHS Scotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.2

1. NICE 2026. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer [TA1169] Published 24 June 2026. Available at: https://www.nice.org.uk/guidance/ta1169 (Accessed November 2026).

1. NICE 2026. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer [TA1169] Published 24 June 2026. Available at: https://www.nice.org.uk/guidance/ta1169 (Accessed November 2026).

*By clicking the link you will leave the AbbVie Pro website to an external website which is not under the control of AbbVie. AbbVie is not responsible for content of any such site or any further links from such site.
NICE, National Institute for Health and Care Excellence;  SMC, Scottish Medicines Consortium.

2. SMC 2026. Mirvetuximab soravtansine is accepted for use within NHSScotland as monotherapy for the treatment of adult patients with folate receptor- alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. Published 12 October 2026 https://scottishmedicines.org.uk/medicines-advice/mirvetuximab-soravtansine-elahere-fullsmc2892/ (Accessed November 2026).

2. SMC 2026. Mirvetuximab soravtansine is accepted for use within NHSScotland as monotherapy for the treatment of adult patients with folate receptor- alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. Published 12 October 2026 https://scottishmedicines.org.uk/medicines-advice/mirvetuximab-soravtansine-elahere-fullsmc2892/ (Accessed November 2026).

UK-ELAH-260245. Date of Preparation: November 2026